Janus Global Life Sciences Fund (JAGLX)

Sector Experts Seeking Growth and Innovation in Health Care

SHARE CLASS

FUND FACTS (JAGLX)

Inception Date12/31/1998
NAV (As of 9/1/15 )$58.42
Total Net Assets (As of 7/31/15)$5.53B
Annual Expense Ratio
(As of fiscal year end 9/30/14)
GROSS 0.93%
NET 0.93%

Performance (As of 6/30/15)
1 Year40.08%
3 Year39.10%
5 Year31.38%
10 Year15.39%
Morningstar (As of 7/31/15)
CategoryHealth
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

123 Funds Rated
Equity
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Quarterly Commentary - Q2 2015

EXECUTIVE SUMMARY

Quarterly returns in health care outpaced those of the broader market, fueled by accelerating innovation as well as industry consolidation.

The Fund outperformed its benchmark for the quarter, led by biotechnology, pharmaceuticals and health care facilities stocks.

Health care equipment and health care supplies detracted from performance.

We believe valuations remain reasonable overall given the sector’s strong fundamentals, though we see some pockets of over-exuberance in the market.

FUND MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996